A multicenter phase 1 study of solitomab (MT110, AMG 110), a bispecific EpCAM/CD3 T-cell engager (BiTE®) antibody construct, in patients with refractory solid tumors
一项针对难治性实体瘤患者的多中心 1 期临床试验，研究对象为双特异性 EpCAM/CD3 T 细胞接合剂 (BiTE®) 抗体构建体 solitomab (MT110, AMG 110)
期刊:Oncoimmunology
影响因子:
doi:10.1080/2162402X.2018.1450710
Maxim Kebenko, Marie-Elisabeth Goebeler, Martin Wolf, Annette Hasenburg, Ruth Seggewiss-Bernhardt, Barbara Ritter, Beate Rautenberg, Djordje Atanackovic, Andrea Kratzer, James B Rottman, Matthias Friedrich, Eva Vieser, Stefanie Elm, Ingrid Patzak, Dorothea Wessiepe, Sabine Stienen, Walter Fiedler
